US-based pharma company Moderna will apply for US and European emergency authorization of its COVID-19 vaccine, based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns.
Finally, time to rejoice ?
The drug company also reported a 100% success rate in preventing severe Covid-19 cases. The filing sets Moderna's product up to be the second vaccine likely to receive US emergency use authorization after Pfizer-BioNTech's vaccine, which is 95% effective.
Of the 196 volunteers who contracted COVID-19 in the more than 30,000-person trial, 185 had received a placebo versus 11 who got the vaccine. The company reported 30 severe cases - all in the placebo group - which means the vaccine was 100% effective at preventing severe cases.
Its distribution of Moderna vaccine is expected to be easier than Pfizer's because while it needs to be stored in a freezer, it does not require the ultra-cold temperature needed by Pfizer's vaccine.
Bottom line: The world is happy; now it's time to watch which countries will get a share of the vaccine!